GlaxoSmithKline in Trouble for Another Misleading Drug Ad

As the huge pharmaceutical company GlaxoSmithKline contends with safety issues concerning its diabetes drug Avandia, it’s also contending with a fresh FDA allegation that it ran false or misleading advertisements about its cancer drug Arzerra. The FDA has cited Glaxo for omitting important information about the drug’s safety and effectiveness. These are basically the same charges Glaxo face in dealing with its diabetes drug Avandia. FDA officials singled out a drug ad which ran in December of last year for failure to reveal any of the drug’s potential side effects including a serious brain infection, pneumonia, fevers and other blood disorders. In response to the FDA concern about Arzerra, a Glaxo spokesperson stated that the ad won’t be used again.